

ORCA Therapeutics to present FIH Clinical Data with enhanced oncolytic immunotherapeutic ORCA-010 at the International Oncolytic Virus Conference

's-Hertogenbosch, the Netherlands, 4 November, 2021.

ORCA Therapeutics B.V., a clinical-stage biopharmaceutical company developing oncolytic immunotherapy to treat cancer will present clinical study results with ORCA's lead compound ORCA-010 at the (virtual) International Oncolytic Virus Conference (IOVC) held in Sedona (USA) from November 5 to November 7.

The IOVC poster will provide an update on the development of ORCA's enhanced oncolytic immunotherapy platform and the ongoing phase I/II clinical trial. The lead compound ORCA-010 is an enhanced oncolytic adenovirus, designed for optimal safety and anti-cancer properties. ORCA-010 is currently in clinical trials in Canada in treatment-naïve patients with localized prostate cancer.

Safety data from the phase I dose escalation study demonstrated excellent safety at all dose levels, with only grade I and grade II adverse events observed. Virus replication is evident as demonstrated by increased levels of shedding analysis in urine. Interim MRI analysis at 6 months post treatment demonstrated that patients with significantly enlarged prostates observed a reduction of prostate volume post treatment.

For more information please visit <http://www.orca-therapeutics.nl/>

Please contact

Kees Groen, PhD., CEO
ORCA Therapeutics B.V.
+31 653648230 info@ORCA-therapeutics.com